Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?

Vijay Parshuram Raturi, Chen Ta Wu, Suhel Mohammad, Hidehiro Hojo, Yanping Bei, Masaki Nakamura, Masayuki Okumura, Toshiya Rachi, Rahul Singh, Rajeev Gupta, Devendra Parmar, Feza Hasan, Jalaj Gaur, Dewesh Kishan, Saurabh Kumar, Avinash Badajena, Pranay Katepogu, Naoyuki Shigematsu

Research output: Contribution to journalArticle

Abstract

Aim: The association of excision repair cross-complementing 1 mRNA (ERCC-1 mRNA) expression with the outcome has been reported with immunohistochemistry (IHC) using tumor tissue in head and neck cancer. We evaluated ERCC-1 mRNA expression by reverse transcription polymerase chain reaction (RT-PCR) from peripheral blood lymphocytes (PBLs) as bio-predictor of locoregional failure (LRF) to chemoradiation (CRT) for locally advanced laryngeal squamous cell cancer (LALSCC). Methods: A total of 107 male patients with LALSCC were enrolled in this prospective study. ERCC-1 mRNA expression by PBLs was determined by RT-PCR. Definitive CRT was delivered with 35 mg/m2 weekly cisplatin. Response Evaluation Criteria in Solid Tumor 1.1 (RECIST 1.1) were used in evaluating treatment response. The primary objective was to assess LRF. The influence of patient characteristics, treatment response, weekly cisplatin cycles, ERCC mRNA expression was determined for LRF, progression-free survival (PFS) and overall survival (OS). Results: A total of 98 patients completed definitive CRT. The median value of 2-ΔΔCT ERCC-1 mRNA expression was 3.9; based on which it was categorized as low and high. Correlation of ERCC-1 expression with treatment response was insignificant (P-.38). With a median follow-up of 33 months; 2-year LRF, PFS, and OS was 63.3%, 34.7% and 79.4%. The 2-year LRF, PFS and OS for low versus high expression were 53.1% versus 73.5% (P-value = 0.036), 44.9% versus 24.4% (P-value = 0.047) and 81.6% versus 77.2% (P-value = 0.33), respectively. In multivariate analysis, ERCC-1 expression, T-stage, N-stage and tumor subsite are predictive factors for LRF; T-stage and nodal recurrence for OS; stage and treatment response for PFS. Conclusion: LALSCC patient with ERCC-1 mRNA low expression was associated with lower LRF rate, and improved PFS.

Original languageEnglish
JournalAsia-Pacific Journal of Clinical Oncology
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Laryngeal Neoplasms
DNA Repair
Cisplatin
Disease-Free Survival
Lymphocytes
Squamous Cell Neoplasms
Messenger RNA
Survival
Reverse Transcription
Polymerase Chain Reaction
Therapeutics
Head and Neck Neoplasms
Neoplasms
Multivariate Analysis
Immunohistochemistry
Prospective Studies
Recurrence

Keywords

  • chemoradiation
  • excision repair cross-complementing group-1
  • locally advanced laryngeal squamous cell carcinoma
  • peripheral blood lymphocytes
  • reverse transcriptase polymerase chain reaction

ASJC Scopus subject areas

  • Oncology

Cite this

Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer? / Raturi, Vijay Parshuram; Wu, Chen Ta; Mohammad, Suhel; Hojo, Hidehiro; Bei, Yanping; Nakamura, Masaki; Okumura, Masayuki; Rachi, Toshiya; Singh, Rahul; Gupta, Rajeev; Parmar, Devendra; Hasan, Feza; Gaur, Jalaj; Kishan, Dewesh; Kumar, Saurabh; Badajena, Avinash; Katepogu, Pranay; Shigematsu, Naoyuki.

In: Asia-Pacific Journal of Clinical Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Raturi, VP, Wu, CT, Mohammad, S, Hojo, H, Bei, Y, Nakamura, M, Okumura, M, Rachi, T, Singh, R, Gupta, R, Parmar, D, Hasan, F, Gaur, J, Kishan, D, Kumar, S, Badajena, A, Katepogu, P & Shigematsu, N 2019, 'Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?', Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13239
Raturi, Vijay Parshuram ; Wu, Chen Ta ; Mohammad, Suhel ; Hojo, Hidehiro ; Bei, Yanping ; Nakamura, Masaki ; Okumura, Masayuki ; Rachi, Toshiya ; Singh, Rahul ; Gupta, Rajeev ; Parmar, Devendra ; Hasan, Feza ; Gaur, Jalaj ; Kishan, Dewesh ; Kumar, Saurabh ; Badajena, Avinash ; Katepogu, Pranay ; Shigematsu, Naoyuki. / Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?. In: Asia-Pacific Journal of Clinical Oncology. 2019.
@article{e56314f6468a414b913e61090dd7f3d4,
title = "Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?",
abstract = "Aim: The association of excision repair cross-complementing 1 mRNA (ERCC-1 mRNA) expression with the outcome has been reported with immunohistochemistry (IHC) using tumor tissue in head and neck cancer. We evaluated ERCC-1 mRNA expression by reverse transcription polymerase chain reaction (RT-PCR) from peripheral blood lymphocytes (PBLs) as bio-predictor of locoregional failure (LRF) to chemoradiation (CRT) for locally advanced laryngeal squamous cell cancer (LALSCC). Methods: A total of 107 male patients with LALSCC were enrolled in this prospective study. ERCC-1 mRNA expression by PBLs was determined by RT-PCR. Definitive CRT was delivered with 35 mg/m2 weekly cisplatin. Response Evaluation Criteria in Solid Tumor 1.1 (RECIST 1.1) were used in evaluating treatment response. The primary objective was to assess LRF. The influence of patient characteristics, treatment response, weekly cisplatin cycles, ERCC mRNA expression was determined for LRF, progression-free survival (PFS) and overall survival (OS). Results: A total of 98 patients completed definitive CRT. The median value of 2-ΔΔCT ERCC-1 mRNA expression was 3.9; based on which it was categorized as low and high. Correlation of ERCC-1 expression with treatment response was insignificant (P-.38). With a median follow-up of 33 months; 2-year LRF, PFS, and OS was 63.3{\%}, 34.7{\%} and 79.4{\%}. The 2-year LRF, PFS and OS for low versus high expression were 53.1{\%} versus 73.5{\%} (P-value = 0.036), 44.9{\%} versus 24.4{\%} (P-value = 0.047) and 81.6{\%} versus 77.2{\%} (P-value = 0.33), respectively. In multivariate analysis, ERCC-1 expression, T-stage, N-stage and tumor subsite are predictive factors for LRF; T-stage and nodal recurrence for OS; stage and treatment response for PFS. Conclusion: LALSCC patient with ERCC-1 mRNA low expression was associated with lower LRF rate, and improved PFS.",
keywords = "chemoradiation, excision repair cross-complementing group-1, locally advanced laryngeal squamous cell carcinoma, peripheral blood lymphocytes, reverse transcriptase polymerase chain reaction",
author = "Raturi, {Vijay Parshuram} and Wu, {Chen Ta} and Suhel Mohammad and Hidehiro Hojo and Yanping Bei and Masaki Nakamura and Masayuki Okumura and Toshiya Rachi and Rahul Singh and Rajeev Gupta and Devendra Parmar and Feza Hasan and Jalaj Gaur and Dewesh Kishan and Saurabh Kumar and Avinash Badajena and Pranay Katepogu and Naoyuki Shigematsu",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ajco.13239",
language = "English",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Could excision repair cross-complementing group-1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?

AU - Raturi, Vijay Parshuram

AU - Wu, Chen Ta

AU - Mohammad, Suhel

AU - Hojo, Hidehiro

AU - Bei, Yanping

AU - Nakamura, Masaki

AU - Okumura, Masayuki

AU - Rachi, Toshiya

AU - Singh, Rahul

AU - Gupta, Rajeev

AU - Parmar, Devendra

AU - Hasan, Feza

AU - Gaur, Jalaj

AU - Kishan, Dewesh

AU - Kumar, Saurabh

AU - Badajena, Avinash

AU - Katepogu, Pranay

AU - Shigematsu, Naoyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: The association of excision repair cross-complementing 1 mRNA (ERCC-1 mRNA) expression with the outcome has been reported with immunohistochemistry (IHC) using tumor tissue in head and neck cancer. We evaluated ERCC-1 mRNA expression by reverse transcription polymerase chain reaction (RT-PCR) from peripheral blood lymphocytes (PBLs) as bio-predictor of locoregional failure (LRF) to chemoradiation (CRT) for locally advanced laryngeal squamous cell cancer (LALSCC). Methods: A total of 107 male patients with LALSCC were enrolled in this prospective study. ERCC-1 mRNA expression by PBLs was determined by RT-PCR. Definitive CRT was delivered with 35 mg/m2 weekly cisplatin. Response Evaluation Criteria in Solid Tumor 1.1 (RECIST 1.1) were used in evaluating treatment response. The primary objective was to assess LRF. The influence of patient characteristics, treatment response, weekly cisplatin cycles, ERCC mRNA expression was determined for LRF, progression-free survival (PFS) and overall survival (OS). Results: A total of 98 patients completed definitive CRT. The median value of 2-ΔΔCT ERCC-1 mRNA expression was 3.9; based on which it was categorized as low and high. Correlation of ERCC-1 expression with treatment response was insignificant (P-.38). With a median follow-up of 33 months; 2-year LRF, PFS, and OS was 63.3%, 34.7% and 79.4%. The 2-year LRF, PFS and OS for low versus high expression were 53.1% versus 73.5% (P-value = 0.036), 44.9% versus 24.4% (P-value = 0.047) and 81.6% versus 77.2% (P-value = 0.33), respectively. In multivariate analysis, ERCC-1 expression, T-stage, N-stage and tumor subsite are predictive factors for LRF; T-stage and nodal recurrence for OS; stage and treatment response for PFS. Conclusion: LALSCC patient with ERCC-1 mRNA low expression was associated with lower LRF rate, and improved PFS.

AB - Aim: The association of excision repair cross-complementing 1 mRNA (ERCC-1 mRNA) expression with the outcome has been reported with immunohistochemistry (IHC) using tumor tissue in head and neck cancer. We evaluated ERCC-1 mRNA expression by reverse transcription polymerase chain reaction (RT-PCR) from peripheral blood lymphocytes (PBLs) as bio-predictor of locoregional failure (LRF) to chemoradiation (CRT) for locally advanced laryngeal squamous cell cancer (LALSCC). Methods: A total of 107 male patients with LALSCC were enrolled in this prospective study. ERCC-1 mRNA expression by PBLs was determined by RT-PCR. Definitive CRT was delivered with 35 mg/m2 weekly cisplatin. Response Evaluation Criteria in Solid Tumor 1.1 (RECIST 1.1) were used in evaluating treatment response. The primary objective was to assess LRF. The influence of patient characteristics, treatment response, weekly cisplatin cycles, ERCC mRNA expression was determined for LRF, progression-free survival (PFS) and overall survival (OS). Results: A total of 98 patients completed definitive CRT. The median value of 2-ΔΔCT ERCC-1 mRNA expression was 3.9; based on which it was categorized as low and high. Correlation of ERCC-1 expression with treatment response was insignificant (P-.38). With a median follow-up of 33 months; 2-year LRF, PFS, and OS was 63.3%, 34.7% and 79.4%. The 2-year LRF, PFS and OS for low versus high expression were 53.1% versus 73.5% (P-value = 0.036), 44.9% versus 24.4% (P-value = 0.047) and 81.6% versus 77.2% (P-value = 0.33), respectively. In multivariate analysis, ERCC-1 expression, T-stage, N-stage and tumor subsite are predictive factors for LRF; T-stage and nodal recurrence for OS; stage and treatment response for PFS. Conclusion: LALSCC patient with ERCC-1 mRNA low expression was associated with lower LRF rate, and improved PFS.

KW - chemoradiation

KW - excision repair cross-complementing group-1

KW - locally advanced laryngeal squamous cell carcinoma

KW - peripheral blood lymphocytes

KW - reverse transcriptase polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=85074326191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074326191&partnerID=8YFLogxK

U2 - 10.1111/ajco.13239

DO - 10.1111/ajco.13239

M3 - Article

C2 - 31612639

AN - SCOPUS:85074326191

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

ER -